A safe and easy test to instantly transform your asthma care
Using FeNO testing as your asthma risk estimator can help reduce exacerbations by up to 50%.4
Understanding the level of inflammation with FeNO can lead to improved asthma care.
Studies have shown that FeNO testing is a cost-effective way to improve patient outcomes.
FeNO stands for fractional exhaled nitric oxide (NO). NO is a molecule produced by the lungs that can be measured in exhaled breath. The use of NO in medicine was a real breakthrough, leading to a Nobel Prize in 1998.
Although asthma is traditionally diagnosed with tools that measure airway obstruction, it's actually an inflammatory condition.1
As research progresses, opinion is changing. It is now understood that up to 84% of asthma patients have Type 2 airway inflammation.2
Understanding the level of inflammation with FeNO can lead to improved asthma care. FeNO levels are elevated in asthma and can provide healthcare professionals with the opportunity to see inside a patient’s lungs at the point-of-care.
With half of asthma cases misdiagnosed, lung function testing is not enough to make a decision.2 Asthma diagnosis is 7x more likely with a high FeNO level.3
She gets breathless when she runs and occasionally at night. Lucy made an appointment to see her doctor to understand what was going on.
The doctor performed routine lung function testing and would have ruled out asthma. However when Lucy performed a FeNO test, the result was 73ppb, indicating airway inflammation.
This suggests that Lucy may have asthma.
A high FeNO level indicates a greater risk of exacerbation. Using FeNO testing as your asthma risk estimator can help reduce exacerbations by up to 50%.4
He has had asthma since the age of 3 and is prescribed an inhaled corticosteroid. Victor still experiences exacerbations and recently visited his doctor.
The doctor wanted to check whether Victor was using his inhaler properly and offered him a FeNO test. Victor had a FeNO level of 163ppb, showing he is non-adherent to his medication and at risk of severe exacerbations. Seeing this number showed Victor how bad the situation actually was.
As part of his asthma management plan, Victor tested his FeNO regularly with the aim of reducing his FeNO to a normal level. Seeing his FeNO level reduce at every appointment motivated Victor to keep taking his medication. Victor’s FeNO is now 24ppb, his inflammation is under control and he has not had an asthma attack in the last year.
Exacerbation risks can be increased by modifiable factors such as high airway inflammation, reduced lung function, poor adherence to ICS or inadequate inhaler technique.1 Elevated FeNO values are associated with 3.2x greater risk of exacerbations when compared to low FeNO levels.4 Aiming to reduce high FeNO levels can help improve patient outcomes.5
Severe AsthmaRequest a quote for a device today with our simple and easy to use quotation tool. Used by thousands of healthcare professionals, NIOX® is the global device of choice for FeNO testing.6
Request a QuoteAt NIOX® we are passionate about providing excellent support and training.
1. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2021 update.
2. Kavanagh J et al. Over- and under-diagnosis in asthma. Breathe (Sheff). 2019;15(1):e20-e27.
3. Wang Z et al. Agency for Healthcare Research and Quality (AHRQ). The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management. Comparative Effectiveness Reviews, 197. 2017.
4. Petsky HL et al. Tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils): a systematic review and meta-analysis. Thorax. 2018;73(12):1110-1119.
5. Dweik RA et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FeNO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-15.
6. NIOX®. Data on File; MKT-DOF-007. 2026.
7. Menzies-Gow A et al. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633.
8. NIOX®. NHS England Asthma data 2022 (AST001). QOF database. Available at; https://www.gpcontract.co.uk/browse/ENG/Asthma/22. Accessed; May 2023.